Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Homeowners insurance doesn't cover floods: How to protect your home in North Carolina
Recommended
Top two magnet schools in the US are in Wake County
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Coya Therapeutics, Inc. - Common Stock
(NQ:
COYA
)
8.600
+0.170 (+2.02%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
25,224
Open
8.520
Bid (Size)
8.420 (7)
Ask (Size)
8.600 (3)
Prev. Close
8.430
Today's Range
8.400 - 8.750
52wk Range
3.210 - 10.69
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
April 26, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
April 22, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Performance
YTD
+23.56%
+23.56%
1 Month
-10.88%
-10.88%
3 Month
+39.84%
+39.84%
6 Month
+84.95%
+84.95%
1 Year
+86.15%
+86.15%
More News
Read More
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
April 18, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
April 08, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023
March 19, 2024
Via
InvestorPlace
Coya Therapeutics
February 29, 2024
Via
Talk Markets
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
March 19, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Participate in BTIG Fireside Discussion
March 12, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
March 12, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
March 06, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
February 29, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
February 22, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”
February 21, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
February 13, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases
February 05, 2024
Via
Benzinga
Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference
January 29, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series
January 18, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis
January 16, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
January 05, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.
December 20, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
December 13, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Closing of $26.5 Million Private Placement
December 12, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces $26.5 Million Private Placement
December 06, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
December 06, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
December 04, 2023
Via
MarketBeat
Topics
Bonds
Exposures
Debt Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.